liver fibrosis epidemiology forecast

DelveInsight’s ‘Liver Fibrosis- Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Liver Fibrosis Disease Understanding

Liver fibrosis results in the accumulation of extracellular matrix (ECM) proteins, mostly collagens Type I and Type III, followed by the formation of fibrous scar, which can ultimately compromise normal liver function. The main causes of liver fibrosis include alcohol abuse, chronic HCV infection, Non-alcoholic fatty liver disease, and NASH (Fatty Liver not due to alcohol use).

Regardless of the etiology, liver fibrosis is characterized by common molecular mechanisms such as hepatocyte death, chronic inflammation with cytokine release, activation of HSCs, and disruption of the epithelial or endothelial barrier.

Liver Fibrosis Diagnosis

Fibrosis is a precursor to cirrhosis, and establishing the severity of liver fibrosis helps predict liver-related morbidity and mortality and the emergence of complications of portal hypertension. Noninvasive methods to estimate hepatic fibrosis are commonly used in clinical practice as a safer, more accessible, and less costly strategy than liver biopsy for stratifying persons according to risk. These methods include indirect biomarkers, direct biomarkers, and elastography. If a combination of noninvasive methods provides a clear-cut assessment of hepatic fibrosis, further assessment with liver biopsy is generally not needed. Although liver biopsy with histologic analysis has long been considered the gold standard evaluation of hepatic fibrosis, it is now infrequently used to evaluate liver fibrosis in persons with chronic HCV. In the current era, the optimal approach to fibrosis assessment is to use noninvasive serum markers/tests in conjunction with transient elastography.

Continued in the report…..

Liver Fibrosis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Fibrosis, Severity-specific Diagnosed Cases of Non Alcoholic Steatohepatitis (NASH), Total Diagnosed Prevalent cases of Liver Fibrosis in NASH, in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2021 to 2034.

Liver Fibrosis Detailed Epidemiology Segmentation

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Liver Fibrosis in the 7MM were 19,126,579 in 2021.
• The highest total diagnosed prevalent cases of Liver Fibrosis were accounted by the US in 2021 (9,488,135 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Liver Fibrosis with 1,641,162 cases, followed by Italy, which had prevalent population of 1,532,651 in 2021. On the other hand, Spain had the lowest prevalent population (1,307,582 cases).
• Japan had 2,299,149 total diagnosed prevalent cases of Liver Fibrosis in 2021, accounting for approximately 12% in 7MM.

Scope of the Report

• The report covers the descriptive overview of Liver Fibrosis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• The report assesses the disease risk and burden of Liver Fibrosis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights

• 10-year forecast of Liver Fibrosis
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Liver Fibrosis
• Severity-specific Diagnosed Prevalent Cases of NASH
• Diagnosed Prevalent Cases of NASH-specific Liver Fibrosis

Key Questions Answered

• What are the disease risk and burden of Liver Fibrosis?
• What is the historical Liver Fibrosis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Liver Fibrosis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Liver Fibrosis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Liver Fibrosis during the forecast period (2025-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

The Liver Fibrosis report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM+ Liver Fibrosis epidemiology forecast.
• The Liver Fibrosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Liver Fibrosis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Patient Segmentation based on Severity-specific
• Patient Segmentation based on NASH-specific